Overview

A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches

Status:
Terminated

Trial end date:
2009-10-01

Target enrollment:

Participant gender:

Summary

To study the effect of Rozerem, a high affinity MT1 and MT2, low affinity 5-HT2B receptor agonist used for insomnia, as a migraine prophylactic agent.

Phase:

Phase 4

Details

Lead Sponsor:

Charlottesville Neuroscience

Collaborator:

Takeda Pharmaceuticals North America, Inc.